1. Home
  2. NNNN vs LOKV Comparison

NNNN vs LOKV Comparison

Compare NNNN & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNNN
  • LOKV
  • Stock Information
  • Founded
  • NNNN 2021
  • LOKV 2024
  • Country
  • NNNN Germany
  • LOKV United States
  • Employees
  • NNNN N/A
  • LOKV N/A
  • Industry
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • LOKV
  • Sector
  • NNNN Health Care
  • LOKV
  • Exchange
  • NNNN Nasdaq
  • LOKV Nasdaq
  • Market Cap
  • NNNN 267.7M
  • LOKV 288.1M
  • IPO Year
  • NNNN 2025
  • LOKV 2025
  • Fundamental
  • Price
  • NNNN $6.43
  • LOKV $10.05
  • Analyst Decision
  • NNNN
  • LOKV
  • Analyst Count
  • NNNN 0
  • LOKV 0
  • Target Price
  • NNNN N/A
  • LOKV N/A
  • AVG Volume (30 Days)
  • NNNN 28.8K
  • LOKV 7.9K
  • Earning Date
  • NNNN 01-01-0001
  • LOKV 01-01-0001
  • Dividend Yield
  • NNNN N/A
  • LOKV N/A
  • EPS Growth
  • NNNN N/A
  • LOKV N/A
  • EPS
  • NNNN 0.06
  • LOKV N/A
  • Revenue
  • NNNN $8,185,146.00
  • LOKV N/A
  • Revenue This Year
  • NNNN N/A
  • LOKV N/A
  • Revenue Next Year
  • NNNN N/A
  • LOKV N/A
  • P/E Ratio
  • NNNN $118.17
  • LOKV N/A
  • Revenue Growth
  • NNNN 21.95
  • LOKV N/A
  • 52 Week Low
  • NNNN $5.18
  • LOKV $9.80
  • 52 Week High
  • NNNN $7.82
  • LOKV $10.25
  • Technical
  • Relative Strength Index (RSI)
  • NNNN N/A
  • LOKV N/A
  • Support Level
  • NNNN N/A
  • LOKV N/A
  • Resistance Level
  • NNNN N/A
  • LOKV N/A
  • Average True Range (ATR)
  • NNNN 0.00
  • LOKV 0.00
  • MACD
  • NNNN 0.00
  • LOKV 0.00
  • Stochastic Oscillator
  • NNNN 0.00
  • LOKV 0.00

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About LOKV Live Oak Acquisition Corp. V Class A Ordinary Shares

Live Oak Acquisition Corp V is a blank check company.

Share on Social Networks: